Werewolf Therapeutics Statistics
Share Statistics
Werewolf Therapeutics has 44.56M shares outstanding. The number of shares has increased by 4.27% in one year.
| Shares Outstanding | 44.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.97% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.93M |
| Failed to Deliver (FTD) Shares | 153 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 1.52M, so 3.42% of the outstanding shares have been sold short.
| Short Interest | 1.52M |
| Short % of Shares Out | 3.42% |
| Short % of Float | 4.63% |
| Short Ratio (days to cover) | 3.32 |
Valuation Ratios
The PE ratio is -3.68 and the forward PE ratio is -1.18.
| PE Ratio | -3.68 |
| Forward PE | -1.18 |
| PS Ratio | 6.9 |
| Forward PS | 3.6 |
| PB Ratio | 1.24 |
| P/FCF Ratio | -4.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Werewolf Therapeutics Inc. has an Enterprise Value (EV) of 55.18M.
| EV / Earnings | -1.48 |
| EV / Sales | 2.77 |
| EV / EBITDA | -1.7 |
| EV / EBIT | -1.36 |
| EV / FCF | -1.65 |
Financial Position
The company has a current ratio of 7.14, with a Debt / Equity ratio of 0.35.
| Current Ratio | 7.14 |
| Quick Ratio | 7.14 |
| Debt / Equity | 0.35 |
| Total Debt / Capitalization | 26.09 |
| Cash Flow / Debt | -0.83 |
| Interest Coverage | -12.9 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -24.8%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | -24.8% |
| Revenue Per Employee | 443.18K |
| Profits Per Employee | -830.40K |
| Employee Count | 45 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -72.05% in the last 52 weeks. The beta is 0.41, so Werewolf Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | -72.05% |
| 50-Day Moving Average | 1.81 |
| 200-Day Moving Average | 2.99 |
| Relative Strength Index (RSI) | 33.2 |
| Average Volume (20 Days) | 822.14K |
Income Statement
In the last 12 months, Werewolf Therapeutics had revenue of 19.94M and earned -37.37M in profits. Earnings per share was -1.05.
| Revenue | 19.94M |
| Gross Profit | -18.96M |
| Operating Income | -40.50M |
| Net Income | -37.37M |
| EBITDA | -32.47M |
| EBIT | -40.50M |
| Earnings Per Share (EPS) | -1.05 |
Balance Sheet
The company has 134.34M in cash and 51.92M in debt, giving a net cash position of 82.42M.
| Cash & Cash Equivalents | 134.34M |
| Total Debt | 51.92M |
| Net Cash | 82.42M |
| Retained Earnings | -344.07M |
| Total Assets | 140.04M |
| Working Capital | 113.37M |
Cash Flow
In the last 12 months, operating cash flow was -32.61M and capital expenditures -769.00K, giving a free cash flow of -33.38M.
| Operating Cash Flow | -32.61M |
| Capital Expenditures | -769.00K |
| Free Cash Flow | -33.38M |
| FCF Per Share | -0.94 |
Margins
Gross margin is -95.09%, with operating and profit margins of -203.09% and -187.37%.
| Gross Margin | -95.09% |
| Operating Margin | -203.09% |
| Pretax Margin | -187.37% |
| Profit Margin | -187.37% |
| EBITDA Margin | -162.79% |
| EBIT Margin | -203.09% |
| FCF Margin | -167.38% |
Dividends & Yields
HOWL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -77.78% |
| FCF Yield | -55.49% |
Analyst Forecast
The average price target for HOWL is $9.5, which is 603.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 603.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -3.47 |
| Piotroski F-Score | 2 |